Stalicla Secures CHF 2 Million Backing From Addex Therapeutics To Advance Targeted Treatments For Neuropsychiatric Disorders

Addex Therapeutics, a clinical-stage biopharmaceutical company specializing in small molecule allosteric modulators for neurological disorders, has announced a CHF 2 million investment in Stalicla, a clinical-stage company developing precision medicine treatments for neurodevelopmental and neuropsychiatric conditions. The funding will help Stalicla advance its autism-focused drug pipeline, support partnership activities for selected assets, prepare for a Series C funding round, and fund general corporate operations.

As part of the investment, Addex CEO Tim Dyer has joined Stalicla’s Board of Directors and has been nominated as Chairman. This strategic move aligns with Addex’s broader commitment to advancing precision therapies in the central nervous system (CNS) space. Stalicla is preparing to initiate Phase 2 clinical trials for its lead autism candidate, STP1, and a second asset, both targeting specific subgroups within the autism spectrum disorder (ASD) population. 

Tim Dyer, CEO of Addex, stated, “This strategic investment underscores Addex’s commitment to advancing innovative treatments for CNS disorders and builds on our 20% equity holding in Neurosterix. Stalicla has built a world leading precision medicine platform in neurodevelopmental disorders, backed by a strong portfolio of clinical-stage assets. We look forward to providing our industry expertise to support the Stalica team as they bring forward these new treatment options for this underserved patient population.”

Lynn Durham, CEO of Stalicla, mentioned, “We are delighted to welcome Addex and its syndicate of investors to Stalicla. Addex brings a wealth of life science expertise and we look forward to working with them to build significant value for our shareholders. Stalicla is poised to advance a number of assets into phase 2 clinical studies for subpopulations of patients with ASD and is committed to transforming the lives of these patients and their families.”

In addition, the company is progressing its STP7 program, which involves mavoglurant, an mGluR5 negative allosteric modulator for the treatment of cocaine use disorder. This program is being developed in collaboration with the U.S. National Institute on Drug Abuse (NIDA) under a CRADA and is currently the most advanced treatment candidate for this indication. The investment highlights Addex’s strategic intent to support innovative CNS drug development and strengthens its position in the growing field of precision neurotherapeutics.